MEIP News and Press, MEI Pharma Inc. From 03/25/22

Gainers: Clever Leaves Holdings (CLVR) +33%. NextDecade (NEXT) +23%. Dynagas LNG (DLNG) +23%. Clarus Therapeutics (CRXT) +23%. Amylyx (AMLX) +20%. Hoegh LNG Partners LP (HMLP) +21%. Kidpik (PIK) +19%. Agrify (AGFY) +17%. NexImmune (NEXI) +17%. Joby Aviation (JOBY) +17%. Losers: Icosavax (ICVX...

Clinical-stage biotech, MEI Pharma (NASDAQ:MEIP -59.2%) has recorded the biggest intraday loss in over seven years as Wall Street reacts to the regulatory setback for the company’s cancer medication, zandelisib developed in partnership with Kyowa Kirin (OTCPK:KYKOF). With FDA requiring...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re checking in on the latest penny stocks news today with two that investors are watching fall on Friday. Source: Shutterstock Falling penny stocks come as no surprise considering the volatility the space su...

Gainers: Clever Leaves (CLVR) +28%. Tilray Brands (TLRY) +13%. Cutera (CUTR) +11%. STRATA Skin Sciences (SSKN) +10%. Clarus Therapeutics (CRXT) +8%. Losers: MEI Pharma (MEIP) -58%. Icosavax (ICVX) -50%. Rezolute (RZLT) -9%. Alpha Tau Medical (...

MEI Pharma (MEIP) -46% on setback to U.S. marketing application for lymphoma therapy. The Honest Company (HNST) -18% on Q4 earnings release. Cyren (CYRN) -15% on Q4 earnings release. Orion Office REIT (ONL) -12% on Q4 earnings release. Indones...

The late-stage biotech MEI Pharma (NASDAQ:MEIP) has lost ~44% in the pre-market Friday after disclosing that the current data will not be adequate to support a marketing application in the U.S. for zandelisib, a phosphatidylinositol-3-kinase (“PI3K”) inhibitor drug can...

– MEI to Host Zandelisib Program Update Webcast Today at 4:30 p.m. Eastern Time – MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administration (FDA) to dis...

GreenWood Investors is a mostly-long, deep value investment firm focused on areas of extreme pessimism, structural inefficiencies and low competition. Our fourth quarter performance reflected a worldwide capitulation away from nearly everything except the large tech companies. We ...

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from two oncology drug candidates in its pipeline will be presented at the upcoming American Association for Cancer Re...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...